Carole R. Berini, PhD, and Saamir Pasha, MPH, of Ontada discuss a model designed to estimate missing baseline ECOG performance status in advanced prostate cancer and the validation needed before it can support broader real-world evidence research.
|Podcasts|August 21, 2020
Pharmacy Focus Episode 5: The Ever Changing Role of Emergency Medicine Pharmacists
The Pharmacy Times® Pharmacy Focus podcast provides the latest industry news and information, thought-leader insights, clinical updates, patient counseling tools, and innovative solutions for the everyday practice and business of pharmacy.
Advertisement
In this week’s episode, we will be discussing emergency medicine pharmacists. Email your pharmacy hero nomination to [email protected]!
Advertisement
Related to this article
A biologic stewardship framework can enhance consistency, safety, and sustainability of biologic use in health systems.
Thomas Hope, MD, explains why radioligand therapies should be evaluated according to whether their clinical benefits outweigh their risks within the context of patients’ available cancer treatment options.
The approval is supported by data from the phase 3 FINE-ONE clinical trial.
The randomized ALLIANCE A051701 trial closed early when treatment-related toxicity and mortality were increased without improving PFS in patients with newly diagnosed double-hit lymphoma.
Robin Tumlinson, PharmD, BCOP, discusses how rapidly expanding bladder cancer options are creating new questions around treatment sequencing, toxicity management, biomarker testing, and multidisciplinary care.
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Pharmacists are well equipped to manage DOAC therapy by providing initial education, adherence support, and safety monitoring.
Advertisement
Advertisement
Trending on Pharmacy Times
1
How Pharmacists Overcome PCSK9 Inhibitor Access Barriers
2
Adult Pneumococcal Immunizations: A Practical Guide for Pharmacists
3
From Reactive to Proactive: AI's Role in Modern Pharmacy Safety
4
Trial Ended Early When Venetoclax Plus DA-EPOCH-R Did Not Improve Outcomes in Double-Hit Lymphoma
5